PTC Therapeutics (PTCT) Reiterated Buy at Citi Ahead of Risdiplam Data
Tweet Send to a Friend
Citi analyst Joel Beatty reiterated a Buy rating and $62.00 price target on PTC Therapeutics (NASDAQ: PTCT) ahead of of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
